Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.89) by 41.57 percent. This is a 8.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $27.767 million which beat the analyst consensus estimate of $23.711 million by 17.11 percent.